Exacerbations requiring oral corticosteroids ‐ adults · people with asthma
Formoterol probably leads to lower patients with an exacerbation requiring a course of oral… compared with short‐acting beta2‐agonist (moderate certainty).
1 finding from 1 review
Fatal serious adverse events · people with asthma
Formoterol showed no clear difference in fatal serious adverse events (all‐cause) compared with short‐acting beta2‐agonist (low certainty).
1 finding from 1 review
Patients with a serious adverse event (all cause) · people with asthma
Formoterol showed no clear difference in patients with a serious adverse event (all cause) compared with short‐acting beta2‐agonist (low certainty).
1 finding from 1 review
Asthma‐related serious adverse event · people with asthma
Formoterol showed no clear difference in patients with a serious adverse event (asthma related) compared with short‐acting beta2‐agonist (low certainty).
1 finding from 1 review
Withdrawals due to any reason · people with asthma
Formoterol may leads to higher withdrawals (any reason) compared with short‐acting beta2‐agonist (low certainty).
1 finding from 1 review
CMV disease · solid organ transplant recipients
Extended probably leads to lower CMV disease compared with short‐duration valganciclovir (moderate certainty).
1 finding from 1 review
All‐cause death · solid organ transplant recipients
Extended showed no clear difference in all‐cause death compared with short‐duration valganciclovir (low certainty).
1 finding from 1 review
CMV syndrome · solid organ transplant recipients
Extended probably leads to lower CMV syndrome compared with short‐duration valganciclovir (moderate certainty).
1 finding from 1 review
CMV infection · solid organ transplant recipients
Extended may leads to lower CMV infection compared with short‐duration valganciclovir (low certainty).
1 finding from 1 review
Acute rejection · solid organ transplant recipients
Extended probably leads to lower acute rejection compared with short‐duration valganciclovir (moderate certainty).
1 finding from 1 review
Opportunistic infections · solid organ transplant recipients
Extended showed no clear difference in opportunistic infections compared with short‐duration valganciclovir (low certainty).
1 finding from 1 review
Total treatment‐related adverse effects · solid organ transplant recipients
Extended showed no clear difference in total treatment‐related adverse effects compared with short‐duration valganciclovir (moderate certainty).
1 finding from 1 review
Depressive symptomatology (lower = less depressive symptomatology): end‐of‐intervention · older people with depression
1 finding from 1 review
Treatment non‐acceptability (higher = greater non‐acceptability): end‐of‐intervention · older people with depression
1 finding from 1 review
Depression remission · older people with depression
1 finding from 1 review
Quality of life or psychological well‐being (higher = higher quality of life or psychological well‐being): end‐of‐intervention · older people with depression
1 finding from 1 review
Anxious symptomatology (lower = less anxious symptomatology): end‐of‐intervention · older people with depression
1 finding from 1 review
Outcomes ( · men with Peyronie's disease (palpable plaque or pain)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Patient‐reported ability to have intercourse · men with Peyronie's disease (palpable plaque or pain)
It is very uncertain whether injectional verapamil changes patient‐reported ability to have intercourse compared with saline (short‐term) (very low certainty).
1 finding from 1 review
Quality of life · men with Peyronie's disease (palpable plaque or pain)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found